Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)

P-174: Outcomes of Patients with Newly Diagnosed Myeloma Cast Nephropathy in the Modern Era-A Retrospective Cohort Study

P-318: A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma

P-319: First-Line Treatment Landscape in Multiple Myeloma: Analysis of Stem Cell Transplantation and Drug Utilization in Brazil and Argentina from the TOTEMM-A and TOTEMM-B Real-World Studies

P-320: Real-World Evidence of Proteasome Inhibitors, Immunomodulatory Drugs and Anti-CD38 in Patients with Multiple Myeloma Treated in Brazil: TOTEMM-B Study Insights

P-321: Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

P-322: Non-Cryopreserved Stem Cell Transplantation in Multiple Myeloma (MM) Patients: A Case Series Report

P-323: VRd dosing and outcomes in Indian patients with Newly diagnosed Multiple Myeloma: Report from a propsepctive Clinical study

P-325: In-class transition from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Updated 3-year PFS analysis of US MM-6 overall and by patient (pt) subgroups of interest

P-326: Phase 1b/2 trial of iberdomide in combination with daratumumab, dexamethasone +/- carfilzomib to eliminate MRD after induction therapy and ASCT in NDMM

P-327: REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

P-328: Long-term survival of Multiple Myeloma patients in Brazil

P-329: Diagnostic challenges across the multiple myeloma pathway: perspectives of primary care physicians and orthopedic specialists

P-330: STEM CELL MOBILIZATION STRATEGY WITH PEGILGRASTIM FOR STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A DIRECT COST COMPARISON

P-331: ASCT: A Viable First-Line Treatment Option for Elderly Multiple Myeloma Patients Without Access to New Drugs

P-332: Role of Consolidation Chemotherapy in the Real World for Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)

P-333: Synchronic Occurrence of Multiple Myeloma, POEMS Syndrome and Prostate Adenocarcinoma - is there role for autologous stem cell transplant?

P-334: Ixazomib‐Based Maintenance Therapy in Multiple Myeloma Patients Eligible and Ineligible for Transplantation: A Real‐World Study (INFINITE Study)

P-335: Iberdomide is immune stimulatory and induces deep anti-myeloma activity across doses in combination with daratumumab in patients with TNE NDMM from the CC-220-MM-001 study

P-337: Lower utilisation of Autologous Stem Cell Transplant in patients with Multiple Myeloma from Black Caribbean and Black African ethnic groups in the UK – a single center experience

P-338: High frequency of electrolyte derangement and low frequency of transfusion requirement post melphalan autologous bone marrow transplant – a single center experience

P-339: Tandem autologous transplantation can overcome the poor prognosis of double-hit multiple myeloma patients with 1q21 gain/amp and t(4;14)

P-340: Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma

P-341: Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD): A Prospective, Open-Label, Multicenter, Phase 2 Study

P-342: Impact of achieving

P-343: Safety and Efficacy of Dara-KAD induction followed with tandem ASCT and KP maintenance in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia

P-344: A single-arm prospective study of the combination of KAPD induction with or without ASCT and KP maintenance for newly diagnosed extramedullary multiple myeloma

P-345: A prospective cohort study of the effect of second-line induction intensification in suboptimal responders to first-line induction in newly diagnosed transplantation eligible multiple myeloma

P-346: Cryoglobulinemic vasculitis with gangrene as an initial presentation of Multiple myeloma

P-347: Renal Outcomes and Predictive Analysis of Progression in Newly Diagnosed Multiple Myeloma Patients

P-348: Time to treatment initiation among Black and White older adults with multiple myeloma: A SEER-Medicare analysis

P-349: Multiple Myeloma patients who are in VGPR or better benefits from continued treatment with zoledronic acid beyond two years.

P-350: A retrospective comparison of single versus tandem transplant in newly diagnosed Multiple Myeloma: a real-world study

P-351: SINGLE VS TANDEM TRANSPLANT IN HIGH-RISK MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SINGLE-CENTRE ANALYSIS

P-352: Impact of Obesity on Outcomes of Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant

P-353: Stem-Cell Mobilization and Transplantation in Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib-Lenalidomide-Dexamethasone With or Without Isatuximab: Results From the IsKia Trial

P-354: Real-world comparison of progression free survival and time to next therapy endpoints in newly diagnosed patients with multiple myeloma

P-355: Melphalan vs Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as preparative regimen for newly diagnosed patients with Multiple Myeloma undergoing Autologous stem cell transplant.

P-356: Prognostic impact of t(11;14) in newly diagnosed patients with multiple myeloma

P-357: Outcomes of multiple myeloma patients with prior solid tumors undergoing an autologous transplant

P-358: Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation

P-359: Survival of patients with multiple myeloma treated with bortezomib-based triplets and autologous hematopoietic stem cell transplant as frontline in Latin America.

P-360: IMPACT OF DARATUMUMAB/BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (DVTD) INDUCTION THERAPY ON CHEMO-FREE STEM CELL MOBILIZATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL LIFE EXPERIENCE

P-361: Busulfan Plus Melphalan versus Melphalan Alone as Conditioning Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Long-Term Follow Up of a Randomized Phase III Trial

P-362: A Real-World Study to Assess Treatment Patterns of Patients with 2L+ Relapsed or Refractory Multiple Myeloma in Italy, Germany, and the United Kingdom

P-363: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-eligible Patients With Multiple Myeloma: A Pooled Analysis of Patients Aged ≥65 Years From Both PERSEUS and GRIFFIN Studies

P-364: A Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years

P-365: Serious and hematological adverse effects of daratumumab plus triple therapy vs triple therapy alone for Multiple Myeloma: A Systematic Review and Meta-Analysis

P-366: Pre-Transplant Factors Predict Long-Term Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation in a Resource-Limited Setting

P-367: COST ANALYSIS FOR ADULT PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION

P-368: Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study

P-369: OPTIMIZING THE ALCYONE TRIAL: EFFICACY OF DARATUMUMAB AND BORTEZOMIB MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS POST DARA-VMP INDUCTION, 1 YEAR ANALYSIS

P-370: Autologous Stem Cell Transplantation in Multiple Myeloma Patients with Renal Impairment: A Retrospective Analysis

P-371: Bortezomib thalidomide dexamethasone as first-line treatment in Newly Multiple Myeloma Patients in Perú.

P-372: Treatment of multiple myeloma in the public health system in Brazil: results of 9 years of treatment

P-374: Real World Analysis Over 15 Years of Newly Diagnosed Multiple Myeloma in China

P-375: The significance and predictive performance of gait speed and grip strength in dynamic frailty assessment of newly diagnosed transplant non-eligible elderly patients with multiple myeloma

P-376: Gait speed, grip strength, and clinical outcomes in newly diagnosed transplant non-eligible elderly patients with multiple myeloma

P-377: Impact of weekly versus twice weekly bortezomib on rates of peripheral neuropathy in combination with lenalidomide, dexamethasone and daratumumab

P-378: A retrospective study of serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors treatments

P-426: Isatuximab, plus bortezomib, lenalidomide, and dexamethasone (VRd) for newly diagnosed multiple myeloma (NDMM) transplant-ineligible patients: frailty subgroup analysis of IMROZ